Japan Lung Cancer Market Set to Experience Robust Growth, Projected to Reach US$ 9.38 Billion by 2032 | Astute Analytica

The 𝐉𝐚𝐩𝐚𝐧 𝐥𝐮𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫 𝐦𝐚𝐫𝐤𝐞𝐭 is poised for significant growth, with revenues anticipated to rise from approximately 𝐔𝐒$ 𝟑,𝟑𝟐𝟖.𝟎𝟐 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟑 to an impressive 𝐔𝐒$ 𝟗,𝟑𝟕𝟔.𝟖𝟑 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟐. This represents a robust compound annual growth rate (𝐂𝐀𝐆𝐑) 𝐨𝐟 𝟏𝟐.𝟒𝟔% during the forecast period from 𝟐𝟎𝟐𝟒 𝐭𝐨 𝟐𝟎𝟑𝟐.

𝐓𝐡𝐞 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:- https://www.astuteanalytica.com/request-sample/japan-lung-cancer-market

Lung cancer, one of the leading causes of cancer-related deaths globally, continues to drive substantial demand for advanced diagnostic tools, treatments, and therapies in Japan. As the country grapples with an aging population and increasing awareness about lung cancer, innovations in treatment modalities such as targeted therapies, immunotherapies, and advancements in early detection techniques are expected to contribute significantly to market growth.

The market's expansion is further supported by government initiatives, improved healthcare infrastructure, and rising investments in lung cancer research. The growing adoption of precision medicine and the increasing number of clinical trials focusing on lung cancer treatments are also expected to play a key role in the overall market development.

𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬

𝐃𝐫𝐢𝐯𝐞𝐫: 𝐑𝐢𝐬𝐢𝐧𝐠 𝐈𝐧𝐜𝐢𝐝𝐞𝐧𝐜𝐞 𝐨𝐟 𝐋𝐮𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫

The increasing incidence of lung cancer in Japan is a significant driver of growth in the country's lung cancer market. Persistent environmental and lifestyle challenges, particularly high smoking rates, are exacerbating the healthcare burden and necessitating advancements in treatments, diagnostics, and infrastructure. Lung cancer remains the second most common cancer in Japan, with 136,723 new cases reported in 2022, according to the International Agency for Research on Cancer (IARC). Globally, Japan ranked third in lung cancer incidence, presenting a substantial opportunity for pharmaceutical companies, healthcare providers, and diagnostic tool manufacturers.

A key contributor to Japan's elevated lung cancer rates is the country's longstanding smoking culture. Despite ongoing efforts to reduce tobacco consumption, data from the World Bank and the WHO indicate that in 2022, 18.6 million Japanese citizens aged 15 and above were tobacco users, placing Japan among the top global consumers of tobacco. In 2023, 18.9% of Japanese adults were regular smokers, with 12.4% using heated tobacco products (HTPs) and 7.4% engaging in dual use. This continued prevalence of smoking highlights the need for targeted treatment strategies in the lung cancer market.

𝐅𝐨𝐫 𝐦𝐨𝐫𝐞 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐭𝐡𝐞 𝐉𝐚𝐩𝐚𝐧 𝐥𝐮𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫 𝐦𝐚𝐫𝐤𝐞𝐭, 𝐩𝐥𝐞𝐚𝐬𝐞 𝐜𝐨𝐧𝐭𝐚𝐜𝐭:- https://www.astuteanalytica.com/industry-report/japan-lung-cancer-market

Environmental factors, such as air pollution from industrial emissions and vehicles in densely populated urban centers like Tokyo and Osaka, further compound Japan's lung cancer problem. Poor air quality, linked to over 42,000 deaths in 2019, has been strongly correlated with the rising lung cancer rates, prompting healthcare providers to adopt low dose computed tomography (LDCT) for early detection in high-risk populations.

With cancer cases projected to rise by 13.1% by 2050, lung cancer is expected to remain a major concern, reinforcing the demand for innovative therapies and diagnostic solutions, and creating substantial growth potential in Japan's lung cancer market.

𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐧 𝐉𝐚𝐩𝐚𝐧 𝐋𝐮𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐌𝐚𝐫𝐤𝐞𝐭

• Accuray Incorporated
• Intuitive Surgical Inc
• Karl Storz SE & Co. KG
• Medtronic plc
• Olympus Corporation
• Teleflex Incorporated
• AngioDynamics Inc.
• Dunlee
• Amoy Diagnostics Co., Ltd.
• Medicaroid Corporation
• Other Prominent Players

𝐒𝐞𝐠𝐦𝐞𝐧𝐭 𝐁𝐫𝐞𝐚𝐤𝐝𝐨𝐰𝐧:

𝐁𝐲 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 & 𝐓𝐡𝐞𝐫𝐚𝐩𝐲

• Diagnostics
• Bronchoscopy
• TTNA
• Imaging
• Tumor Biomarker Test
• In Situ Hybridization
• Others
• Therapy
• Non-invasive
• Immunotherapy
• Targeted therapy
• Chemotherapy
• Radiation Therapy
• Minimally invasive
• Radiofrequency ablation
• Microwave ablation
• Thermal/cryoablation
• Others
• Surgery
• Thoracotomy
• Lobectomy
• Sleeve Resection
• Segmentectomy
• Pneumenectomy

𝐁𝐲 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐲𝐩𝐞

• Small Cell Lung Cancer
• Non-small Cell Lung Cancer
• Lung Carcinoid Tumour

𝐁𝐲 𝐄𝐧𝐝 𝐔𝐬𝐞𝐫

• Hospitals and Specialty Centres
• Diagnostic Laboratories
• Others

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭@- https://www.astuteanalytica.com/request-sample/japan-lung-cancer-market

𝐀𝐛𝐨𝐮𝐭 𝐀𝐬𝐭𝐮𝐭𝐞 𝐀𝐧𝐚𝐥𝐲𝐭𝐢𝐜𝐚:

Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth, and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the globe.

They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyse for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of the best cost-effective, value-added package from us, should you decide to engage with us.

𝐆𝐞𝐭 𝐢𝐧 𝐭𝐨𝐮𝐜𝐡 𝐰𝐢𝐭𝐡 𝐮𝐬

𝐏𝐡𝐨𝐧𝐞 𝐧𝐮𝐦𝐛𝐞𝐫: +18884296757
𝐄𝐦𝐚𝐢𝐥: sales@astuteanalytica.com
𝐕𝐢𝐬𝐢𝐭 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: https://www.astuteanalytica.com/

This release was published on openPR.